Free Trial

Citius Pharmaceuticals (CTXR) Competitors

Citius Pharmaceuticals logo
$1.64 -0.04 (-2.14%)
As of 11:05 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CTXR vs. KLRS, IMMX, IZTC, ASRT, EQ, UNCY, VXRT, XBIT, RPTX, and COEP

Should you be buying Citius Pharmaceuticals stock or one of its competitors? The main competitors of Citius Pharmaceuticals include Kalaris Therapeutics (KLRS), Immix Biopharma (IMMX), Invizyne Technologies (IZTC), Assertio (ASRT), Equillium (EQ), Unicycive Therapeutics (UNCY), Vaxart (VXRT), XBiotech (XBIT), Repare Therapeutics (RPTX), and Coeptis Therapeutics (COEP). These companies are all part of the "pharmaceutical products" industry.

Citius Pharmaceuticals vs. Its Competitors

Citius Pharmaceuticals (NASDAQ:CTXR) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

16.9% of Citius Pharmaceuticals shares are owned by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 10.7% of Citius Pharmaceuticals shares are owned by company insiders. Comparatively, 75.0% of Kalaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Citius Pharmaceuticals' return on equity of -60.03% beat Kalaris Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Citius PharmaceuticalsN/A -60.03% -33.83%
Kalaris Therapeutics N/A -81.02%-65.15%

Citius Pharmaceuticals has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Kalaris Therapeutics has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500.

Citius Pharmaceuticals presently has a consensus price target of $53.00, indicating a potential upside of 3,141.59%. Kalaris Therapeutics has a consensus price target of $3.00, indicating a potential downside of 33.63%. Given Citius Pharmaceuticals' higher possible upside, research analysts plainly believe Citius Pharmaceuticals is more favorable than Kalaris Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Citius Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20
Kalaris Therapeutics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.33

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Citius PharmaceuticalsN/AN/A-$39.14MN/AN/A
Kalaris TherapeuticsN/AN/A-$58.77MN/AN/A

In the previous week, Citius Pharmaceuticals had 6 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 6 mentions for Citius Pharmaceuticals and 0 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 0.67 beat Citius Pharmaceuticals' score of 0.43 indicating that Kalaris Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Citius Pharmaceuticals Neutral
Kalaris Therapeutics Positive

Summary

Citius Pharmaceuticals beats Kalaris Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Citius Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CTXR vs. The Competition

MetricCitius PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$27.82M$2.97B$6.21B$10.63B
Dividend YieldN/A57.79%5.74%4.88%
P/E RatioN/A23.6529.0727.24
Price / SalesN/A776.79581.06183.55
Price / CashN/A171.3937.5161.65
Price / Book0.165.4012.256.56
Net Income-$39.14M$33.06M$3.32B$276.14M
7 Day Performance17.63%-1.83%0.19%-1.08%
1 Month Performance40.95%6.67%6.61%1.88%
1 Year Performance-82.28%-3.02%61.48%32.92%

Citius Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CTXR
Citius Pharmaceuticals
2.8056 of 5 stars
$1.64
-2.7%
$53.00
+3,141.6%
-82.5%$27.82MN/A0.0020News Coverage
Gap Down
KLRS
Kalaris Therapeutics
1.2952 of 5 stars
$4.76
+7.0%
$3.00
-37.0%
N/A$83.23MN/A0.00110
IMMX
Immix Biopharma
3.2648 of 5 stars
$2.50
flat
$8.00
+220.0%
+98.8%$82.59MN/A-3.259
IZTC
Invizyne Technologies
N/A$12.95
-4.1%
N/AN/A$80.96MN/A0.0029
ASRT
Assertio
2.8792 of 5 stars
$0.84
+0.9%
$2.38
+182.0%
-27.8%$80.36M$124.96M-1.8720Positive News
EQ
Equillium
0.4782 of 5 stars
$1.28
-4.5%
$1.00
-21.9%
+23.2%$79.73M$41.10M-2.2940News Coverage
Short Interest ↑
UNCY
Unicycive Therapeutics
2.6846 of 5 stars
$4.49
+1.1%
$57.00
+1,169.5%
+13.6%$78.42M$680K-1.099
VXRT
Vaxart
1.7628 of 5 stars
$0.34
-2.4%
$2.00
+489.6%
-53.8%$77.66M$47.40M-1.26120
XBIT
XBiotech
1.809 of 5 stars
$2.56
+0.8%
N/A-65.8%$77.44M$4.01M-2.78100News Coverage
Short Interest ↓
Gap Up
RPTX
Repare Therapeutics
2.7794 of 5 stars
$1.82
+1.1%
$4.50
+147.3%
-47.8%$77.33M$53.48M-0.71180
COEP
Coeptis Therapeutics
0.9487 of 5 stars
$15.55
-1.0%
N/A+238.1%$75.68MN/A-2.682News Coverage
Short Interest ↑

Related Companies and Tools


This page (NASDAQ:CTXR) was last updated on 10/22/2025 by MarketBeat.com Staff
From Our Partners